Sodium chloride supplement at diagnosis and during infancy in children with salt-losing 21-hydroxylase deficiency
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Eight infants (6 female, 2 male) with salt-losing congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency were studied to determine the sodium deficit at diagnosis and the level of salt supplement required in addition to subsequent hormone replacement. The median sodium deficit at diagnosis was 34 mmol (range 16-78) or 10.5 mmol/kg (range 4-24). A mean sodium supplement of 2.2 mmol/kg per day (range 0.5-4.9), double the amount provided with feeds, was required to maintain plasma sodium concentration and plasma renin activity (PRA) in the normal range for age. We present an equation based on sodium output (urine), sodium input (feeding plus supplement) and plasma sodium concentration to calculate the sodium supplement needed to maintain sodium balance on hormone replacement in this condition and some practical management suggestions. The necessity for salt supplements is often underestimated and the salt-losing tendency exacerbated by infection remains an unnecessary reason for hospitalization during the first months of life. In patients with salt-losing CAH life-long mineralocorticoid treatment is necessary but additional salt supplements are needed to maintain plasma sodium concentration and PRA in the normal range during infancy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in patients with salt-wasting CAH, this amount is insufficient, and sodium chloride supplements are recommended (182).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [182]
Citations
Cites
MENARD, J. *., & CATT, K. J. (1972) · Endocrinology · doi:10.1210/endo-90-2-422 · Cited by 454 · cited 1×
“PRA (pmol ml 1 h-Z) was measured by a radio-immunoassay of angiotensin I as described by Menhard and Catt [18].”
MethodDarrow, D. C., & Yannet, H. (1935) · Journal of Clinical Investigation · doi:10.1172/jci100674 · Cited by 271 · cited 1×
“is the TBW [9] and the plasma sodium concentration is determined by the total body sodium content and the TBW [3, 9, 15].”
BackgroundCOMPOSITION OF HUMAN COLOSTRUM AND MILK
MACY, I. G. (1949) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.1949.02030050604009 · Cited by 194 · cited 1×
“In addition, the normal environment encountered by the infant is one in which availability of dietary sodium is limited, since breast and formula milk have a low sodium content of approximately 8 and 8-12mmol/1 respectively [16].”
BackgroundMolecular and clinical advances in congenital adrenal hyperplasia
Miller, W. L., & Levine, L. S. (1987) · The Journal of Pediatrics · doi:10.1016/s0022-3476(87)80334-7 · Cited by 178 · cited 2×
“21-Hydroxylase deficiency may present as the classical salt-losing or simple virilizing type of congenital adrenal hyperplasia (CAH) and in a variety of mild non-classical forms [19].”
BackgroundKominami, S., Ochi, H., Kobayashi, Y., & Takemori, S. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85711-3 · Cited by 171
RÖSLER, A., LEVINE, L. S., SCHNEIDER, B., NOVOGRODER, M., & NEW, M. I. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-45-3-500 · Cited by 122
Matteson, K. J., Phillips, J. A., Miller, W. L., Chung, B. C., Orlando, P. J., Frisch, H., Ferrandez, A., & Burr, I. M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5858 · Cited by 104 · cited 1×
“DNA studies have shown that gene deletions are not a common cause of the salt-losing variety and indicate that the salt-losing phenotype is due to many different lesions resulting in inactivation of the P-450c21B gene [ 17 ].”
BackgroundPlasma renin activity and aldosterone concentration in the human newborn.
Dillon, M. J., Gillin, M. E., Ryness, J. M., & de Swiet, M. (1976) · Archives of Disease in Childhood · doi:10.1136/adc.51.7.537 · Cited by 104 · cited 2×
“As our data show clearly, PRA tends to normal values for age [4] on addi-”
BackgroundManagement of congenital adrenal hyperplasia.
Hughes, I. A. (1988) · Archives of Disease in Childhood · doi:10.1136/adc.63.11.1399 · Cited by 61 · cited 1×
“The treatment of 21-hydroxylase deficiency is wellestablished and consists primarily of replacement of the deficient steroid hormones [11, 25].”
Background
Research works printed but not linked: 2
- Chaptal J, Jean R, Guillaumot R, Morel G (1963) Etude statistique de l'elimination urnaire des electrolytes chez l'enfant normal a differents ages. Arch Fr Pediatr 20:905–931
- Prader A (1954) Der Genitalbefund beim Pseudohermaphroditismus femininus des kongenitalen adrenogenitalen Syndroms. Morphologie, Häufigkeit, Entwicklung und Vererbung der verschiedenen Genitalformen. Helv Paediatr Acta 9:231–243
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
(2002) · Hormone Research in Paediatrics · doi:10.1159/000065490 · Cited by 458
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Forest, M. G. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh047 · Cited by 200
Adrenal Steroidogenesis and Congenital Adrenal Hyperplasia
Turcu, A. F., & Auchus, R. J. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.02.002 · Cited by 177
“Infants with the most severe (salt-wasting) forms of disease need higher mineralocorticoid doses and additionally require supplementation with sodium chloride (1–2 g sodium chloride daily) while the renal function matures.(111) Mineralocorticoid replacement is generally maintained but occasionally becomes unnecessary…”
BackgroundRoche, E. F., Charmandari, E., Dattani, M. T., & Hindmarsh, P. C. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01757.x · Cited by 113
“Finally, we did not conduct salt balance studies in these individuals, which may be of importance, although salt supplementation tends to be confined only to the first year of life (Mullis et al., 1990).”
Self-citationManagement of the child with congenital adrenal hyperplasia
Hindmarsh, P. C. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.010 · Cited by 120
Self-citationLongitudinal analysis of growth and puberty in 21-hydroxylase deficiency patients
Van der Kamp, H. J. (2002) · Archives of Disease in Childhood · doi:10.1136/adc.87.2.139 · Cited by 104
Newborn screening for congenital adrenal hyperplasia in New Zealand
Cutfield, W. S., & WEBSTER, D. R. (1995) · The Journal of Pediatrics · doi:10.1016/s0022-3476(95)70513-9 · Cited by 77
Current and Novel Treatment Strategies in Children with Congenital Adrenal Hyperplasia
Nordenström, A., Falhammar, H., & Lajić, S. (2022) · Hormone Research in Paediatrics · doi:10.1159/000522260 · Cited by 41
“Adding a sodium chloride solu-tion (0.23 g/L, dose 2 mL/kg a day, or 2 mmol/kg a day) is necessary for small children with SW CAH, at least during the first year of life because of renal immaturity and mineralocorticoid resistance [1, 39, 40].”
BackgroundInfluentialClinical guidelines for the diagnosis and treatment of 21-hydroxylase deficiency (2021 revision)
Ishii, T., Kashimada, K., Amano, N., Takasawa, K., Nakamura‐Utsunomiya, A., Yatsuga, S., Mukai, T., Ida, S., Isobe, M., Fukushi, M., et al. (2022) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.2022-0009 · Cited by 37
“During the neonatal and early infantile periods, relative mineralocorticoid resistance occurs because of immature tubular reabsorption of sodium; thus, administration of sodium chloride in addition to FC is required for salt-wasting forms (10, 11, 111, 112).”
BackgroundHonour, J. W., & Rumsby, G. (1993) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(93)90124-f · Cited by 28
Management of Disorders of Sex Development
Hewitt, J. K., & Warne, G. L. (2009) · Pediatric Health · doi:10.2217/17455111.3.1.51 · Cited by 26
Bonfig, W., Roehl, F., Riedl, S., Brämswig, J., Richter-Unruh, A., Fricke-Otto, S., Hübner, A., Bettendorf, M., Schönau, E., Dörr, H., et al. (2018) · Hormone Research in Paediatrics · doi:10.1159/000481775 · Cited by 25
Brook, C. G. D. (1990) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1990.tb03893.x · Cited by 25
Self-citationCreighton, S. (2003) · Hormone Research in Paediatrics · doi:10.1159/000070228 · Cited by 19
“Sodium chloride supplements are often needed in infancy, at 1–3 gm/d (17–51 mEq/d), distributed in several feedings ( 23 ).”
BackgroundCreighton, S., Ransley, P. G., Duffy, P. G., Wilcox, D. T., Mushtaq, I., Cuckow, P. M., Woodhouse, C. R. J., Minto, C. L., Crouch, N. S., Stanhope, R. G., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030127 · Cited by 19
Self-citationNeumann, U., van der Linde, A., Krone, R. E., Krone, N. P., Güven, A., Güran, T., Elsedfy, H. H., Poyrazoglu, S., Darendeliler, F., Bachega, T. A. S. S., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1085 · Cited by 18
Blood Pressure in Children with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
Balagamage, C., Lawrence, N., Krone, R. E., Bacila, I. A., & Krone, N. P. (2023) · Hormone Research in Paediatrics · doi:10.1159/000533465 · Cited by 13
“Thus, infants with SW-CAH have a higher risk of hyponatremia, and should be treated with additional salt supplements at a dose of approximately 2 g/day [47, 66].”
Long-term Growth in Congenital Adrenal Hyperplasia
Maheshwari, A., Khadilkar, V. V., Gangodkar, P. V., & Khadilkar, A. V. (2018) · The Indian Journal of Pediatrics · doi:10.1007/s12098-018-2753-6 · Cited by 11
Kendırcı, H. N. P., Ünal, E., Dündar, İ., Buluş, A. D., Güneş, S. O., & Şıklar, Z. (2024) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2024.2024-6-26-s · Cited by 11
“Salt solution or NaCl tablets containing approximately 1-2 g/day of NaCl (17-34 mmol/ day, up to 10 mmol/day of Na) should be given in divided doses (26).”
Treatment Outcomes in Congenital Adrenal Hyperplasia
Cheng, T. Q., & Speiser, P. (2012) · Advances in Pediatrics · doi:10.1016/j.yapd.2012.04.009 · Cited by 9
“However, in patients with salt-wasting CAH, the sodium content in breast milk or infant formulas is insufficient to maintain plasma sodium levels and plasma renin activity in the normal range [26].”
BackgroundPark, S.-H. (2019) · The Analyst · doi:10.1039/c9an00555b · Cited by 4
Espinasse-Holder, M., Vanderbecken, S., Cartigny, M., Stuckens, C., & Weill, J. (1999) · Archives de Pédiatrie · doi:10.1016/s0929-693x(00)86983-3 · Cited by 3
Textbook of Neonatal Medicine: A Chinese Perspective
YU, V. Y. H., Feng, Z., Tsang, R. C., & Yeung, C. (1996) · Project Muse (Johns Hopkins University) · Cited by 3
Bethin, K. E., & Muglia, L. J. (2013) · Humana Press eBooks · doi:10.1007/978-1-60761-395-4_12 · Cited by 4
The Medical Management of Disorders of Sex Development
Warne, G. L., & Hewitt, J. K. (2011) · Springer eBooks · doi:10.1007/978-3-642-22964-0_16 · Cited by 2
Disorders of the Adrenal Gland
Fechner, P. Y. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-40139-5.00096-6 · Cited by 3
Disorders of the Adrenal Gland
Nimkarn, S., & New, M. I. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0134-0.10091-5 · Cited by 3
Congenital Adrenal Hyperplasia in the Adolescent
Kim, M. S., Liang, M. C., Kokorowski, P. K., Tseng, T., Koppin, C. M., & Geffner, M. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-14881-1_59 · Cited by 2
Bethin, K. E., Majumdar, I., & Muglia, L. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_10 · Cited by 2
Disorders of the Adrenal Gland
Fechner, P. Y. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-82823-9.00084-2 · Cited by 1
Clinical practice guidelines "Congenital adrenal hyperplasia in children" with comments
Чугунов, І., Kopylova, I., Kolodkina, A. A., Kalinchenko, N. Y., Vorontsova, M. V., Bezlepkina, O. B., Peterkova, V. A., & Mokrysheva, N. G. (2026) · Problems of Endocrinology · doi:10.14341/probl13767 · Cited by 1
Disorders of the Adrenal Gland
Bethin, K. E., & Muglia, L. J. (2005) · Elsevier eBooks · doi:10.1016/b978-072169347-7.50092-5 · Cited by 1
Congenital Adrenal Hyperplasia in the Adolescent
Kim, M. S., Tseng, T., Koppin, C. M., & Geffner, M. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-17002-2_59-1 · Cited by 1
O’Connell, M. A., Hutson, J. M., & Grover, S. R. (2020) · Springer eBooks · doi:10.1007/978-981-13-7864-5_16 · Cited by 3
Bethin, K. E., Majumdar, I., & Muglia, L. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-73782-9_13 · Cited by 2
Delay in Diagnosis of Congenital Adrenal Hyperplasia in an Acutely III Infant
Zeitler, P. S. (1995) · Clinical Pediatrics · doi:10.1177/000992289503401106 · Cited by 1
Nermoen, I. (2013) · NVA (Nasjonalt vitenarkiv)
Dörr, H. G. (2015) · Elsevier eBooks · doi:10.1016/b978-3-437-22107-1.50270-3
Bhatnagar, R., Siddiqui, S. A., Rai, P. L., Tomar, V., Verma, M. K., & Sharma, P. (2019) · Tropical Doctor · doi:10.1177/0049475519879592
“0mmol/kg/day).(9,10) Mineralocorticoid doses vary during infancy owing to improvement in sensitivity which improves with age and particularly during the first year of life.”
BackgroundEndokrinologische Erkrankungen
(2011) · Elsevier eBooks · doi:10.1016/b978-3-437-22702-8.50013-3
Congenital Adrenal Hyperplasia in the Adolescent
Kim, M. S., Tseng, T., Koppin, C. M., & Geffner, M. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-17798-4_59
21-Hydroxylase Deficiency: Clinical and Biochemical Aspects
Nordenström, A., & Lajić, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65208-x
Congenital Adrenal Hyperplasia in the Adolescent
Kim, M. S., Liang, M. C., Kokorowski, P. K., Tseng, T., Koppin, C. M., & Geffner, M. E. (2022) · Springer eBooks · doi:10.1007/978-3-319-17002-2_59-2
Honour, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818124-9.00004-8
Disorders of the Adrenal Gland in Children and Adolescents
Katugampola, H., & Krone, N. P. (2023) · Endocrinology · doi:10.1007/978-3-030-18901-3_4-1
Disorders of the Adrenal Gland in Children and Adolescents
Katugampola, H., & Krone, N. P. (2024) · Endocrinology · doi:10.1007/978-3-030-23709-7_4
21-Hydroxylase deficiency: Clinical and biochemical aspects
Nordenström, A., & Lajić, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00171-0
Congenital Adrenal Hyperplasia
Witchel, S. F., Oberfield, S. E., Fisher, A. S., & Trapp, C. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-66296-6_11
Corticosteroids in Pediatric Endocrinology
Giannini, C., & Mohn, A. (2015) · Springer eBooks · doi:10.1007/978-3-319-16056-6_11
Metadata
- Authors
- Mullis, P. E., Hindmarsh, P. C., & Brook, C. G. D.
- ORCID
- Hindmarsh, P. C.
- Venue
- European Journal of Pediatrics
- Published
- 1990-11
- Volume
- 150
- Issue
- 1
- Pages
- 22-25
- ISSN
- 0340-6199 (ISSN-L)
- 1432-1076
- OpenAlex
- W1997000704
- Cited by
- 53
- References
- 25
- Citations by year
- 2026: 1 · 2024: 5 · 2023: 5 · 2022: 4 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 5 · 2017: 2 · 2016: 1 · 2015: 3 · 2013: 2 · 2012: 1
- FWCI
- 0.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Pediatrics (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Nephrology › Electrolyte and hormonal disorders
- Keywords
- salt-losing congenital adrenal hyperplasia, 21-hydroxylase deficiency, sodium chloride supplementation, sodium deficiency, plasma sodium, plasma renin activity, mineralocorticoid replacement therapy, sodium balance, infancy
- MeSH terms
- Adrenal Hyperplasia, Congenital, Female, Fludrocortisone, Humans, Hydrocortisone, Infant, Newborn, Male, Sodium Chloride, Sodium, Dietary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.